Journal: Pharmaceutics

Article Title: Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators

doi: 10.3390/pharmaceutics15010182

Figure Lengend Snippet: Input parameters and optimized parameters for the PBPK model of tegoprazan and the metabolite M1.

Article Snippet: They were predicted to be 2.32 for tegoprazan and 2.10 for M1 (ChemAxon), 2.91 for tegoprazan, and 2.67 for M1 (ALOGPS) [ , ].

Techniques: Molecular Weight, Clinical Proteomics, Solubility, Permeability, PAMPA Assay, Recombinant, Dissolution

Journal: Pharmaceutics

Article Title: Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators

doi: 10.3390/pharmaceutics15010182

Figure Lengend Snippet: In terms of the training dataset, the predicted and observed plasma concentration–time curves of tegoprazan and the metabolite M1 after the oral administration of tegoprazan in healthy subjects are shown. Solid lines are the predicted values of each model. Circles are clinical observations. Details on dosing regimens, characteristics, subject demographics, and references are listed in . The PK profile of M1 in the ID 09 was not used for model development. The simulation for M1 in this ID was performed based on the developed PBPK models of tegoprazan and M1.

Article Snippet: They were predicted to be 2.32 for tegoprazan and 2.10 for M1 (ChemAxon), 2.91 for tegoprazan, and 2.67 for M1 (ALOGPS) [ , ].

Techniques: Clinical Proteomics, Concentration Assay

Journal: Pharmaceutics

Article Title: Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators

doi: 10.3390/pharmaceutics15010182

Figure Lengend Snippet: In terms of the test dataset, the predicted and observed plasma concentration–time curves of tegoprazan and the metabolite M1 after the oral administration of tegoprazan in healthy subjects are shown. Solid lines are the predicted values of each model. Circles are clinical observations. Details on dosing regimens, characteristics, subject demographics, and references are listed in .

Article Snippet: They were predicted to be 2.32 for tegoprazan and 2.10 for M1 (ChemAxon), 2.91 for tegoprazan, and 2.67 for M1 (ALOGPS) [ , ].

Techniques: Clinical Proteomics, Concentration Assay

Journal: Pharmaceutics

Article Title: Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators

doi: 10.3390/pharmaceutics15010182

Figure Lengend Snippet: Goodness-of-fit plots for the developed PBPK model of tegoprazan for the prediction of ( A ) plasma concentration, ( B ) Cmax, and ( C ) AUC inf . The line of identity is presented as a solid line; 1.25-fold dimensions and 2.0-fold dimensions are shown using dotted lines and dashed lines, respectively.

Article Snippet: They were predicted to be 2.32 for tegoprazan and 2.10 for M1 (ChemAxon), 2.91 for tegoprazan, and 2.67 for M1 (ALOGPS) [ , ].

Techniques: Clinical Proteomics, Concentration Assay

Journal: Pharmaceutics

Article Title: Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators

doi: 10.3390/pharmaceutics15010182

Figure Lengend Snippet: Sensitivity analysis of the developed PBPK model of tegoprazan and M1 to single parameters, calculated as the change in the AUC inf of ( upper ) tegoprazan and ( lower ) M1 following a single oral dose of tegoprazan 50 mg under fasted state.

Article Snippet: They were predicted to be 2.32 for tegoprazan and 2.10 for M1 (ChemAxon), 2.91 for tegoprazan, and 2.67 for M1 (ALOGPS) [ , ].

Techniques:

Journal: Pharmaceutics

Article Title: Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators

doi: 10.3390/pharmaceutics15010182

Figure Lengend Snippet: Predicted PK parameters of tegoprazan following oral administration of tegoprazan (50 mg, QD) with CYP3A4 perpetrators.

Article Snippet: They were predicted to be 2.32 for tegoprazan and 2.10 for M1 (ChemAxon), 2.91 for tegoprazan, and 2.67 for M1 (ALOGPS) [ , ].

Techniques:

Journal: Pharmaceutics

Article Title: Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators

doi: 10.3390/pharmaceutics15010182

Figure Lengend Snippet: Predicted PK parameters of tegoprazan following oral administration of tegoprazan (50 mg, BID) with CYP3A4 perpetrators.

Article Snippet: They were predicted to be 2.32 for tegoprazan and 2.10 for M1 (ChemAxon), 2.91 for tegoprazan, and 2.67 for M1 (ALOGPS) [ , ].

Techniques:

Journal: Pharmaceutics

Article Title: Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators

doi: 10.3390/pharmaceutics15010182

Figure Lengend Snippet: The PK profiles of tegoprazan following the administration of tegoprazan alone or with CYP3A4 perpetrators in a variety of scenarios. ( A ) Tegoprazan, 50 mg, once daily; ( B ) Tegoprazan, 50 mg, twice daily. Dose of clarithromycin: 500 mg, twice or three times daily. Dose of rifampicin: 600 mg, once daily.

Article Snippet: They were predicted to be 2.32 for tegoprazan and 2.10 for M1 (ChemAxon), 2.91 for tegoprazan, and 2.67 for M1 (ALOGPS) [ , ].

Techniques: